Skip to main content
Premium Trial:

Request an Annual Quote

JP Morgan, Generex, AVI BioPharma, New York Academy of Sciences

Premium

RNAi Companies to Present at JP Morgan Conference

The JP Morgan 22nd Annual Healthcare Conference is scheduled for Jan. 12-15 in San Francisco, and a number of RNAi companies are set to present.

Included on the conference’s roster are Alnylam Pharmaceuticals, Ambion, Promega, and Sirna Therapeutics.

Presentations will be webcast and can be found online at http://www.mapdigital.com/jpmorgan/healthcare04/welcome.html


Generex Sunsidiary Presents Data on Antisense Reagents for Cancer

Generex said this week that its subsidiary Antigen Express has presented data on its DNA vaccine technology at the NIH’s Innovative Administrative Systems for Vaccines conference, which took place in December.

According to Generex, the data showed the benefit of using its subsidiary’s Ii protein antisense reagents to induce a T-helper cell response to prostate specific antigens. Generex said that the therapy cured about half a population of mice with aggressive and poorly immunogenic cancer.



AVI West Nile Virus Antisense Drug Safe in Phase I/II Study

AVI BioPharma said last week that a phase I/II trial has shown its West Nile virus antisense drug AVI-4020 is as safe as the company’s other antisense drugs.

The trial enrolled 10 patients, nine of whom received the drug and one of whom received placebo. No safety concerns pertaining to the drug were identified during the study, said AVI.



New York Academy of Sciences Schedules Additional RNAi Symposia


The New York Academy of Sciences has scheduled two follow-up meetings to its October RNAi symposium.

The upcoming meetings are to take place on March 18 and May 27 at the NYAS, and are being organized by Cold Spring Harbor Laboratory’s Greg Hannon and Columbia University’s Tim Bestor, respectively.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.